Solid Biosciences (SLDB) Equity Ratio (2017 - 2024)
Solid Biosciences' Equity Ratio history spans 8 years, with the latest figure at 0.79 for Q3 2024.
- For Q3 2024, Equity Ratio rose 0.9% year-over-year to 0.79; the TTM value through Sep 2024 reached 0.79, up 0.9%, while the annual FY2023 figure was 0.77, 5.71% down from the prior year.
- Equity Ratio for Q3 2024 was 0.79 at Solid Biosciences, down from 0.84 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.9 in Q3 2021 and bottomed at 0.55 in Q3 2020.
- The 5-year median for Equity Ratio is 0.8 (2023), against an average of 0.8.
- The largest annual shift saw Equity Ratio tumbled 33.81% in 2020 before it surged 63.5% in 2021.
- A 5-year view of Equity Ratio shows it stood at 0.77 in 2020, then increased by 16.11% to 0.9 in 2021, then decreased by 9.23% to 0.81 in 2022, then dropped by 5.71% to 0.77 in 2023, then rose by 2.82% to 0.79 in 2024.
- Per Business Quant, the three most recent readings for SLDB's Equity Ratio are 0.79 (Q3 2024), 0.84 (Q2 2024), and 0.85 (Q1 2024).